company background image
A067630 logo

HLB Life Science KOSDAQ:A067630 Stock Report

Last Price

₩10.01k

Market Cap

₩1.2t

7D

22.8%

1Y

6.8%

Updated

21 Nov, 2024

Data

Company Financials

HLB Life Science Co., Ltd.

KOSDAQ:A067630 Stock Report

Market Cap: ₩1.2t

A067630 Stock Overview

Develops and manufactures in vitro diagnostic medical devices and quasi-drugs in South Korea and internationally. More details

A067630 fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health5/6
Dividends0/6

Rewards

Earnings have grown 14.6% per year over the past 5 years

Risk Analysis

Highly volatile share price over the past 3 months compared to the KR market

Shareholders have been diluted in the past year


HLB Life Science Co., Ltd. Competitors

Hanmi Science

KOSE:A008930

₩2.2t

Celltrion Healthcare

KOSDAQ:A091990

₩11.9t

Wonik

KOSDAQ:A032940

₩62.9b

WSI

KOSDAQ:A299170

₩42.8b

Price History & Performance

Summary of all time highs, changes and price drops for HLB Life Science
Historical stock prices
Current Share Price₩10,010.00
52 Week High₩25,000.00
52 Week Low₩7,700.00
Beta0.033
11 Month Change10.36%
3 Month Change-6.45%
1 Year Change6.83%
33 Year Change-19.02%
5 Year Change-16.28%
Change since IPO480.83%

Recent News & Updates

HLB Life Science Co., Ltd.'s (KOSDAQ:067630) Popularity With Investors Under Threat As Stock Sinks 26%

Oct 24
HLB Life Science Co., Ltd.'s (KOSDAQ:067630) Popularity With Investors Under Threat As Stock Sinks 26%

What HLB Life Science Co., Ltd.'s (KOSDAQ:067630) P/S Is Not Telling You

Aug 30
What HLB Life Science Co., Ltd.'s (KOSDAQ:067630) P/S Is Not Telling You

HLB Life Science (KOSDAQ:067630) Shareholders Should Be Cautious Despite Solid Earnings

May 21
HLB Life Science (KOSDAQ:067630) Shareholders Should Be Cautious Despite Solid Earnings

Recent updates

HLB Life Science Co., Ltd.'s (KOSDAQ:067630) Popularity With Investors Under Threat As Stock Sinks 26%

Oct 24
HLB Life Science Co., Ltd.'s (KOSDAQ:067630) Popularity With Investors Under Threat As Stock Sinks 26%

What HLB Life Science Co., Ltd.'s (KOSDAQ:067630) P/S Is Not Telling You

Aug 30
What HLB Life Science Co., Ltd.'s (KOSDAQ:067630) P/S Is Not Telling You

HLB Life Science (KOSDAQ:067630) Shareholders Should Be Cautious Despite Solid Earnings

May 21
HLB Life Science (KOSDAQ:067630) Shareholders Should Be Cautious Despite Solid Earnings

HLB Life Science Co., Ltd.'s (KOSDAQ:067630) 25% Share Price Surge Not Quite Adding Up

Mar 15
HLB Life Science Co., Ltd.'s (KOSDAQ:067630) 25% Share Price Surge Not Quite Adding Up

HLB Life Science (KOSDAQ:067630) Has Debt But No Earnings; Should You Worry?

Apr 12
HLB Life Science (KOSDAQ:067630) Has Debt But No Earnings; Should You Worry?

Did You Participate In Any Of HLB Life Science's (KOSDAQ:067630) Incredible 442% Return?

Feb 14
Did You Participate In Any Of HLB Life Science's (KOSDAQ:067630) Incredible 442% Return?

Is HLB Life Science (KOSDAQ:067630) A Risky Investment?

Jan 10
Is HLB Life Science (KOSDAQ:067630) A Risky Investment?

We're Not So Sure You Should Rely on HLB Life Science's (KOSDAQ:067630) Statutory Earnings

Dec 06
We're Not So Sure You Should Rely on HLB Life Science's (KOSDAQ:067630) Statutory Earnings

Shareholder Returns

A067630KR HealthcareKR Market
7D22.8%3.6%2.3%
1Y6.8%-4.4%-3.8%

Return vs Industry: A067630 exceeded the KR Healthcare industry which returned -4.4% over the past year.

Return vs Market: A067630 exceeded the KR Market which returned -3.8% over the past year.

Price Volatility

Is A067630's price volatile compared to industry and market?
A067630 volatility
A067630 Average Weekly Movement11.6%
Healthcare Industry Average Movement10.1%
Market Average Movement5.7%
10% most volatile stocks in KR Market11.4%
10% least volatile stocks in KR Market2.7%

Stable Share Price: A067630's share price has been volatile over the past 3 months compared to the KR market.

Volatility Over Time: A067630's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of KR stocks.

About the Company

FoundedEmployeesCEOWebsite
1998142Sung-Bo Simwww.hlb-ls.com

HLB Life Science Co., Ltd. develops and manufactures in vitro diagnostic medical devices and quasi-drugs in South Korea and internationally. It also develops Rivoceranib, a small-molecule tyrosine kinase inhibitor for the treatment of various cancers, including gastric cancer, colon cancer, hepatocellular carcinoma, non-small cell lung cancer, breast cancer, mesothelioma, renal cell carcinoma, and neuroendocrine tumors; and Pyrotinib, an anticancer drug that inhibits the proliferation, division, and survival of cancer cells. In addition, the company is involved in the waste heat recovery, cogeneration power generation, facility installation, solar energy, photovoltaic power generation, bioenergy, geothermal energy, waste energy, wind power, and fuel cell businesses, as well as manufactures and sells disposable syringes.

HLB Life Science Co., Ltd. Fundamentals Summary

How do HLB Life Science's earnings and revenue compare to its market cap?
A067630 fundamental statistics
Market cap₩1.17t
Earnings (TTM)-₩9.20b
Revenue (TTM)₩92.87b

12.8x

P/S Ratio

-129.0x

P/E Ratio

Is A067630 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
A067630 income statement (TTM)
Revenue₩92.87b
Cost of Revenue₩95.82b
Gross Profit-₩2.95b
Other Expenses₩6.26b
Earnings-₩9.20b

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-77.58
Gross Margin-3.17%
Net Profit Margin-9.91%
Debt/Equity Ratio33.0%

How did A067630 perform over the long term?

See historical performance and comparison